Australia's largest stock trading and investment forum Australia's #1 stock forum

VLA

Click for more information

0.00%

$1.75 viralytics limited

Lopez If VLA teamed with pharmas other than Merck/BMS , wouldn't...

First 27 Last

Share
Profile

Follow
TassieTwo

1,107 Posts.

5

13/11/17

16:20

Post #: 28744877
Share

Originally posted by Lopez ↑

Hi,

The interim data indicates the efficacy of the combination exceeds the efficacy of Keytruda as a monotherapy in either indication. It also represents the first time that CVA21 has been successfully administered via IV.
In our view these results appear very encouraging for all stakeholders – and not just the collaboration partners Merck and VLA. We believe each of the major developers will be looking at this data very carefully.
We continue to believe CVA21 is a leading candidate for a combination with either Merck’s Keytruda or other checkpoint inhibitors from BMS, AstraZeneca, Genentech, Pfizer or Celgene.

Aloha

Expand

Lopez
If VLA teamed with pharmas other than Merck/BMS , wouldn't they have to start these combination trials all over again ?

VLA Price at posting: 84.0¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

PTR

Petratherm adds $1.6 to the piggybank ahead of SA titanium drilling program

WMG

Western Mines identifies 2 high-grade zones at Mulga Tank in WA

ALR

Altair Minerals hits high-grade copper and gold at Wee MacGregor, QLD

SNG

Siren Gold boosts antimony resource by 66% to 14.5Kt at Auld Creek, NZ

WR1

Winsome scoping study proposes low-cost operation for Adina lithium project

There are more pages in this discussion • 67 more messages in this thread...

First 27 Last

Add VLA (ASX) to my watchlist